Search
Sulpiride
go.drugbank.com/drugs/DB00391ApprovedWithdrawn[A229538] Clinical studies show a greater effect on treating the negative symptoms of schizophrenia rather than positive symptoms at low doses, though the effects are more equal at higher doses.
Glucagon
go.drugbank.com/drugs/DB00040ApprovedInvestigational[L7640,L7643] Glucagon was granted FDA approval on 14 November 1960.[L7631]
Trichloroacetate
go.drugbank.com/drugs/DB11152ApprovedInvestigationalTrichloroacetate is also found in cosmetic treatments and topical formulations as a cauterant, which removes condyloma or warts on the skin.
Lincomycin
go.drugbank.com/drugs/DB01627ApprovedInvestigationalVet approved[A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214]
Arimoclomol
go.drugbank.com/drugs/DB05025Approved[L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).
Bouteloua gracilis pollen
go.drugbank.com/drugs/DB10715ApprovedBouteloua gracilis pollen is the pollen of the Bouteloua gracilis plant. Bouteloua gracilis pollen is mainly used in allergenic testing.
Categories: Non-Standardized Pollen Allergenic ExtractPhalaris minor pollen
go.drugbank.com/drugs/DB10963ApprovedPhalaris minor pollen is the pollen of the Phalaris minor plant. Phalaris minor pollen is mainly used in allergenic testing.
Categories: Non-Standardized Pollen Allergenic ExtractChlorpromazine
go.drugbank.com/drugs/DB00477ApprovedInvestigationalVet approvedThe prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has s...
Mitometh
go.drugbank.com/drugs/DB12117InvestigationalMitometh is under investigation for the treatment of Adenocarcinoma, Oropharyngeal Neoplasms, Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer, and Stage IV Non-small Cell Lung Cancer, among others
Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigational[L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026] … [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc.